期刊
ARCHIVES OF NEUROLOGY
卷 67, 期 11, 页码 1391-1394出版社
AMER MEDICAL ASSOC
DOI: 10.1001/archneurol.2010.157
关键词
-
资金
- Biogen Idec
Objective: To describe a case of successful clinical management of natalizumab-associated progressive multifocal leukoencephalopathy (PML) and immune reconstitution syndrome (IRIS) in a patient with multiple sclerosis. Design: Case report. Setting: University hospital. Patient: A 41-year-old woman with relapsing-remitting multiple sclerosis developed PML after 29 natalizumab infusions. Interventions: Immediate plasma exchange was combined for removal of natalizumab with application of mefloquine and mirtazapine to limit viral replication and oligodendrocyte infection. A subsequent IRIS was treated with glucocorticosteroids. Results: After 3 months of treatment, cerebrospinal fluid tested negative for JC virus. There was a favorable outcome, and the Expanded Disability Status Scale score remained stable at 3.5 compared with before PML. Conclusions: In the setting of early diagnosis and consequent treatment, natalizumab-associated PML can be well managed in some cases. This situation differs from the course of PML in other conditions, eg, after the application of depleting monoclonal antibodies, in which irreversible cellular effects are associated with very high mortality.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据